Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q6PCB5

UPID:
RSBNL_HUMAN

ALTERNATIVE NAMES:
Round spermatid basic protein 1-like protein

ALTERNATIVE UPACC:
Q6PCB5; C9K0P1; Q6ZS58; Q6ZVI9; Q86X48

BACKGROUND:
The protein Lysine-specific demethylase RSBN1L, alternatively known as Round spermatid basic protein 1-like protein, is pivotal in the demethylation of methylated lysine residues on proteins. This activity is essential for the proper regulation of gene expression, influencing key biological processes such as cell differentiation and development.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Lysine-specific demethylase RSBN1L holds the potential to unlock novel therapeutic avenues. Given its critical role in epigenetic regulation, targeting RSBN1L could lead to innovative treatments for diseases where gene expression is disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.